abstract |
The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. Formula (I) (I') wherein n is 1 or 2; R 1 is hydrogen or methyl and is positioned vicinal to the radical R 1 ; R 2 is hydrogen or methyl; R 3 is C 1 -C 3 alkyl; R 4 is hydrogen, C 1 -C 4 alkyl, cyclopropyl, C 3 -C 4 cycloalkylmethyl or fluorinated C 1 -C 4 alkyl; R 5 is hydrogen, fluorine, chlorine, C 1 -C 4 alkyl, fluorinated C 1 -C 4 alkyl, C 1 -C 4 alkoxy or fluorinated C 1 -C 4 alkoxy; and R 6 is hydrogen, fluorine or chlorine. |